by Ed Barocas, Montclair, New Jersey In spring of 2019, I received two awards for my legal work, the New Jersey Law Journal’s Attorney of the Year Award, and the American Civil Liberties Union’s Roger Baldwin Award for a lifetime of defending civil liberties. The ceremonies were beautiful but bittersweet. I had announced my retirement… Read More »
‘Eddie-mechanics’ was my secret to success
Losmapimod as potential COVID-19 treatment?
Our science team has often discussed the potential of therapies for facioscapulohumeral muscular dystrophy to address other conditions such as cancer, based on the biology of the disease. Now we have learned that losmapimod, currently in a Phase 2b clinical trial for FSHD, will be investigated as a treatment for COVID-19. According to a press… Read More »
CEO’s 2020 second quarter report
Mark Stone, the FSHD Society’s president and CEO, reported on the Society’s activities at his second quarter report to stakeholders on May 20, 2020. The webinar recording is now available (click below). He highlighted how the FSHD Society’s research initiatives, International Research Congress, FSHD Connect conference, Voice of the Patient Forum, community support, and fundraising… Read More »
Dyne ramps up its FSHD program
Dyne Therapeutics, a Waltham, Massachusetts, biopharmaceutical company, announced yesterday that it is accelerating its FSHD therapy development program. Here is their press release: Dyne to evaluate therapies targeting genetic cause of FSHD under agreement with international research organization UMONS Leading FSHD researcher Jeffrey Statland, M.D., appointed to Scientific Advisory Board WALTHAM, Mass. – Dyne Therapeutics,… Read More »
Fulcrum update on ReDUX4 trial
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results May 13, 2020 at 7:00 AM EDT CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results… Read More »